- Home
- GLTO vs SNTG Comparison
GLTO vs SNTG Comparison
Compare GLTO & SNTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- SNTG
- Stock Information
- Founded
- GLTO 2011
- SNTG 2009
- Country
- GLTO Denmark
- SNTG China
- Employees
- GLTO N/A
- SNTG N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- SNTG Finance: Consumer Services
- Sector
- GLTO Health Care
- SNTG Finance
- Exchange
- GLTO Nasdaq
- SNTG Nasdaq
- Market Cap
- GLTO 4.5M
- SNTG 4.8M
- IPO Year
- GLTO 2020
- SNTG 2021
- Fundamental
- Price
- GLTO $2.87
- SNTG $2.56
- Analyst Decision
- GLTO Buy
- SNTG
- Analyst Count
- GLTO 1
- SNTG 0
- Target Price
- GLTO $10.00
- SNTG N/A
- AVG Volume (30 Days)
- GLTO 241.8K
- SNTG 4.6M
- Earning Date
- GLTO 10-31-2025
- SNTG 05-14-2025
- Dividend Yield
- GLTO N/A
- SNTG N/A
- EPS Growth
- GLTO N/A
- SNTG N/A
- EPS
- GLTO N/A
- SNTG N/A
- Revenue
- GLTO N/A
- SNTG $107,507.00
- Revenue This Year
- GLTO N/A
- SNTG N/A
- Revenue Next Year
- GLTO N/A
- SNTG N/A
- P/E Ratio
- GLTO N/A
- SNTG N/A
- Revenue Growth
- GLTO N/A
- SNTG N/A
- 52 Week Low
- GLTO $2.01
- SNTG $1.43
- 52 Week High
- GLTO $14.82
- SNTG $12.70
- Technical
- Relative Strength Index (RSI)
- GLTO 40.87
- SNTG 49.91
- Support Level
- GLTO $2.45
- SNTG $2.41
- Resistance Level
- GLTO $3.99
- SNTG $6.90
- Average True Range (ATR)
- GLTO 0.28
- SNTG 1.52
- MACD
- GLTO -0.03
- SNTG 0.11
- Stochastic Oscillator
- GLTO 27.27
- SNTG 8.65
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About SNTG Sentage Holdings Inc.
Sentage Holdings Inc is a financial service provider that offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.